Nahum Méndez-Sánchez, Francisco Vásquez-Fernández, Daniel Zamora-Valdés, Uribe Misael
Hepatocellular carcinoma is a lethal disease that requires a multidisciplinary approach and management. Surgical therapy offers long-term survival; however, few patients are candidates. There has been no accepted systemic therapy for this disease until recently. This article briefly discusses the role of RAS/RAF/MEK/ ERK signaling pathway in the pathogenesis of the disease and the promising role of sorafenib for advanced disease.
Key words. Liver cancer, hepatocellular carcinoma, HCV, HBV, sorafenib